KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Edwards Lifesciences (EW) EBIAT (2016 - 2026)

Edwards Lifesciences has reported EBIAT over the past 17 years, most recently at $91.2 million for Q4 2025.

  • For Q4 2025, EBIAT fell 76.27% year-over-year to $91.2 million; the TTM value through Dec 2025 reached $1.1 billion, down 74.31%, while the annual FY2025 figure was $1.1 billion, 23.1% down from the prior year.
  • EBIAT for Q4 2025 was $91.2 million at Edwards Lifesciences, down from $292.3 million in the prior quarter.
  • Over five years, EBIAT peaked at $3.1 billion in Q3 2024 and troughed at $91.2 million in Q4 2025.
  • A 5-year average of $481.0 million and a median of $347.2 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: surged 816.93% in 2024 and later tumbled 90.48% in 2025.
  • Year by year, EBIAT stood at $335.3 million in 2021, then grew by 18.82% to $398.4 million in 2022, then decreased by 7.2% to $369.7 million in 2023, then grew by 3.95% to $384.3 million in 2024, then crashed by 76.27% to $91.2 million in 2025.
  • Business Quant data shows EBIAT for EW at $91.2 million in Q4 2025, $292.3 million in Q3 2025, and $331.5 million in Q2 2025.